Kornimate/medical-research-clean huggingface dataset:
multidisciplinary approach for high-risk patients leading to early diagnosis of canadians with heart failure

Conditions: Heart Failure

Summary: in the maple-chf trial, patients will be screened for hf risk factors using electronic medical records of participating family physicians to identify patients with potentially undiagnosed hf. participants will then undergo a diagnostic evaluation using a blood sample for a hormone specific to the heart, the natriuretic peptide or nt-probnp; if elevated, a portable cardiac ultrasound (echo) with artificial intelligence (ai) interpretation will be done; both nt-probnp and echo are required for diagnosis in patients with signs and symptoms suggestive of hf. this screening echo coupled with ai reading from us2.ai provides a fast, reliable, and inexpensive report, which is particularly important in our context, where waiting lists for such examinations can reach up to one year.


Eligibility criteria:
inclusion criteria: male or female ≥40 years of age informed consent and at least two additional risk factors for hf: coronary artery disease \[either a previous documented type 1 myocardial infarction or coronary artery bypass grafting or percutaneous coronary intervention or documented stenosis or an epicardial coronary artery (50% left main stem or \>70% left anterior descending, circumflex or right coronary artery) diabetes type 1 or type 2, persistent or permanent atrial fibrillation, previous ischemic or embolic stroke peripheral arterial disease (previous surgical or percutaneous revascularization or documented stenosis \>50% of major peripheral arterial vessel), chronic kidney disease (estimated glomerular filtration rate \ 300mg/g), regular loop diuretic use for \>30 days within 12 months copd (evidenced by one of the following: pfts showing airway obstruction diagnosis by respiratory physician ct scan reporting presence of emphysema, or treatment with national guideline copd therapy). exclusion criteria: inability to give informed consent e.g., due to significant cognitive impairment, previous diagnosis of heart failure (this is any diagnosis of heart failure with any ejection fraction of any cause) renal replacement therapy, anyone who, in the investigators' opinion, is not suitable to participate in the trial for other reasons e.g., a diagnosis which may compromise survival over the study period.
thoracoscopic pleural biopsy in sohag university hospital

Conditions: Pleural Diseases

Summary: this study aims to evaluate the diagnostic efficacy, safety, and clinical outcomes of thoracoscopic pleural biopsy in the management of pleural diseases.


Eligibility criteria:
inclusion criteria: * patients with suspected pleural disease who have been referred for thoracoscopic pleural biopsy * age: adults aged 18 years and older * patients should have undergone necessary preoperative evaluations, including imaging studies (e.g., chest x-ray, ct scan) that indicate a need for biopsy. exclusion criteria: * contraindications to thoracoscopic biopsy: patients with contraindications to thoracoscopic biopsy * infeasibility of procedure: patients with anatomical or physiological factors that make thoracoscopic biopsy technically unfeasible or unsafe (e.g., severe pleural adhesions or distorted anatomy). * alternative diagnoses: patients who have been definitively diagnosed with a condition that does not require thoracoscopic biopsy for further evaluation. * pregnancy: pregnant women may be excluded due to potential risks to the fetus and the need for specific procedural considerations. * inability to provide consent: patients who are unable to provide informed consent due to cognitive impairment, language barriers, or other reasons. * participation in concurrent studies: patients currently participating in other clinical studies that could interfere with the outcomes of this study or affect their eligibility.
trochanter fixation nail advanced (tfna) weight bearing

Conditions: Femur Fracture

Summary: this study documents real life weight bearing in patients treated with a tfna, who are allowed for immediate weight bearing as tolerated.

prospective data will be collected from 30 patients presenting a per- or inter-trochanteric fracture of the femur treated with the tfna. post-operatively patients will be asked to wear a sensor insole in their shoes for up to 3 months after surgical treatment. the sensor insole will be used in both feet and will not have any impact in patient's activities of daily living while allowing real time measurements of weight bearing. in addition to weight bearing measurements, perceived pain (numeric rating scale), mobility (parker mobility score and time up and go test) will be assessed at 6 and 12 weeks after surgical treatment and in conjunction with the standard (routine) of care follow up schedule. in order to investigate the relationship between these variables and the weight bearing measurements, patients or their care takers or assisting family members will be asked to document the daily use of the insole in a diary. finally, over the course of the study, anticipated adverse events (ae) that may affect the healing process will be collected. special attention will be given to implant- or bone-related aes. images from patients with implant- or bone related aes will be collected as per standard of care

Eligibility criteria:
inclusion criteria: * age 18 years and older * patients treated with the tfna; i.e. according to the technique guide and the indications for use, patients who presented any of the following conditions: * stable or unstable pertrochanteric fractures * intertrochanteric fractures * basal neck fractures * combinations of pertrochanteric, intertrochanteric, and basal neck fractures * patients who were able to walk before the fracture and are prescribed full weight bearing as tolerated post-surgery * ability to understand the content of the patient information / informed consent form * willingness and ability to participate in the study according to the clinical investigation plan * signed and dated ethical committee approved written informed consent according to the local regulations exclusion criteria: * patients who are not allowed to full weight bearing as tolerated post-surgery * any condition, which impairs weight bearing (e.g. additional acute fracture on the ipsilateral and/or contralateral side, pain) * patients, who due to their condition, are in opinion of the prinicipal investigator (pi) unable to complete a reliable assessment * pregnancy or women planning to conceive within the study period * participation in any other medical device or medicinal product registry within the previous month that could, in opinion of the pi, influence the results of the present study
theophylline in treating patients with in situ, stage i, or stage ii chronic lymphocytic leukemia

Conditions: Leukemia

Summary: rationale: drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. purpose: phase ii trial to study the effectiveness of theophylline in treating patients who have in situ, stage i, or stage ii chronic lymphocytic leukemia.

objectives: i. determine the response rate in asymptomatic patients with stage 0, i, or ii b-cell chronic lymphocytic leukemia treated with theophylline. ii. determine the toxicity of this treatment in these patients. outline: patients receive oral theophylline daily. daily treatment continues for a maximum of 6 months in the absence of disease progression or unacceptable toxicity. patients are followed every 4 months for 1 year. projected accrual: a total of 35 patients will be accrued for this study over approximately 10 months.

Eligibility criteria:
disease characteristics: histologically proven stage 0, i, or ii b-cell chronic lymphocytic leukemia stable disease that would otherwise be observed patient characteristics: age: 18 and over performance status: ecog 0-2 life expectancy: at least 1 year hematopoietic: absolute lymphocyte count greater than 5,000/mm3 mature lymphocytes with less than 55% prolymphocytes, atypical lymphocytes, or lymphoblasts bone marrow with at least 30% lymphocytes hepatic: no cirrhosis renal: not specified cardiovascular: no history of unstable cardiac arrhythmia no active congestive heart failure other: no history of uncontrolled seizure disorder not pregnant or nursing negative pregnancy test fertile patients must use effective contraception no other concurrent condition that would make life expectancy less than 1 year prior concurrent therapy: biologic therapy: no concurrent interferon alfa chemotherapy: no prior chemotherapy no concurrent chemotherapy endocrine therapy: at least 3 months since prior corticosteroids no concurrent corticosteroids radiotherapy: not specified surgery: not specified

Keywords: stage 0 chronic lymphocytic leukemia stage i chronic lymphocytic leukemia stage ii chronic lymphocytic leukemia b-cell chronic lymphocytic leukemia
telbivudine or tenofovir treatment in hbeag-negative chronic hepatitis b patients based on the roadmap concept

Conditions: Chronic Hepatitis B

Summary: the purpose of this study is to evaluate the efficacy and safety following the roadmap concept strategy with an initial monotherapy using either telbivudine or tenofovir in hbeag negative chb patients. the data from the study should allow for the validation of the roadmap concept in a prospective manner, for both telbivudine and tenofovir treated hbeag negative chb patients. as part of a post-approval commitment to the european health authorities, the data will also be used to provide an optimized clinical treatment strategy for better clinical use of telbivudine in european hbeag negative patients. furthermore, the data from the study will contribute to a better scientific understanding, disease management and treatment of hbeag negative chb patients.


Eligibility criteria:
inclusion criteria: male or female, at least 18 years of age documented compensated hbeag negative chb defined by all of the following: * detectable serum hbsag at screening visit and at least 6 months prior; * hbeag negative at the screening visit with positive hbeab; * serum hbv dna \> 2000 iu/ml serum alt level \> 1×uln and \ 1xuln wtihin last 6 months exclusion criteria: * co-infected with hcv, hdv or hiv. * received treatment of nucleoside or nucleotide drugs at any time * received ifn or other immunomodulatory treatment within six months before screening * pregnant or nursing (lactating) women * clinical signs/symptoms of hepatic decompensation * history of myopathy, myositis or persistent muscle weakness * history of clinical and laboratory evidence of chronic renal insufficency
surgical prevention of atrial fibrillation in patients with rheumatic mitral valve lesion and left atrium enlargement

Conditions: Atrial Fibrillation; Rheumatic Heart Disease

Summary: this study evaluates the safety and efficiency of surgical prevention of atrial fibrillation in patients with valvular heart disease and left atrium enlargement

preservation or appearance of af(atrial fibrillation) after mitral valve surgery substantially reduce the number of excellent and good results of the operation in the long-term period, causing circulatory insufficiency, increased pulmonary hypertension, increasing the risk of thromboembolic events and stroke. significant predictors of af after surgery are the initial size of the left atrium more than 6.0 cm, stenotic lesions and rheumatic genesis of mitral defect. 80% of patients in this group had af during the first year after operation.

Eligibility criteria:
inclusion criteria: * rheumatic mitral valve lesion * the absence a history of af * sinus rhythm * left atrium size more than 6.0 cm exclusion criteria: * refusal to participate in the study * aortic stenosis / regurgitation * coronary atherosclerosis

Keywords: atrial fibrillation radiofrequency ablation prevention of af mitral valve left atrium enlargement cryoablation
famvir for treatment of hearing in unilateral meniere's disease

Conditions: Meniere's Disease

Summary: the specific aim of this study is to determine the efficacy of treatment with famciclovir in unilateral meniere's disease patients, specifically whether hearing can be improved. the investigators will determine the percentage of unilateral meniere's disease patients experiencing an absence of hearing fluctuation after 3 months of treatment with famciclovir as compared to the placebo arm.


Eligibility criteria:
inclusion criteria: * unilateral meniere's disease * 2 vertigo episodes of at least 20 minutes * fluctuating hearing by subjective history and/or audiometric documentation. audiometric documentation is defined as affected ear pure-tone average change from an audiogram at time 1 to time 2 (less than one year apart) of greater than 15 db. * less than 45 db 4-frequency pure-tone average in the affected ear * tinnitus and/or aural fullness * willing to undergo the clinical trial procedures * signed informed consent exclusion criteria: * acute or chronic middle ear disease in either ear * only hearing ear * 4-frequency pure-tone average \> 45 db in either ear * known allergy to famciclovir or any of the ingredients in the formulation * taking oral steroids or receiving it steroids at time of enrollment. if the subject has been on oral steroids/it steroids, 3 months must elapse from last dose to start of treatment in the study * must not have had previous inner ear surgery * history of immunodeficiency diseases such as hiv * history of renal insufficiency or other kidney diseases * a female of child-bearing potential who is pregnant * history of noncompliance to medical regimens * unwilling to or unable to comply with the protocol, including scheduling study evaluations

Keywords: meniere's disease vertigo hearing loss tinnitus anti-viral famciclovir
a non-randomized study of the nighthawk peripheral plaque excision system during plaque excision of peripheral arterial disease

Conditions: Peripheral Vascular Diseases

Summary: to assess the proximity of the catheter to the vessel wall and to correlate excised tissue with images collected by the integrated optical coherence tomography (oct) imaging system. the primary endpoints are correlation between oct images and histological characterization of excised tissue.


Eligibility criteria:
inclusion criteria: 1. patient requires treatment for peripheral arterial disease (pad). 2. patient is willing and able to provide informed consent. 3. patient has at least one focal, de novo infrainguinal lesion in a native vessel. 4. the minimum reference vessel diameter is 2.0 - 4.5 mm, dependent on the nighthawk device used. 5. the lesion is ≥ 50% stenosed by quantitative vascular angiography. 6. the lesion is ≤ 7 cm in length. 7. the patient must be able to take at least one form of anti-platelet or anti-thrombotic therapy. exclusion criteria: 1. patient presents with degree of limb disease or a co-existing medical condition that makes revascularization inappropriate. 2. the patient has diffuse peripheral arterial disease and/or the disease is heavily calcified. 3. patient presents with concomitant disease contraindicating an endovascular intervention. 4. patient is pregnant. 5. the patient has a hypersensitivity to contrast materials that cannot be adequately pretreated.

Keywords: cli critical limb ischemia pad paripheral arterial disease artherosclerosis leg pain cardiovascular atherectomy nighthawk
phase 2 study of velcade (bortezomib) in patients with relapsed follicular lymphoma

Conditions: Relapsed Follicular Lymphoma

Summary: this is a phase 2, two-arm, non-randomized, open-label, multicenter study evaluating the safety and efficacy of 2 velcade-containing regimens. patients will be treated with either a combination of velcade, rituximab, cyclophosphamide, doxorubicin, and prednisone (velcade-r-cap) or a combination of velcade, rituximab, cyclophosphamide, and prednisone (velcade-r-cp) based on investigator preference. following completion of the treatment period, patients will receive maintenance therapy with rituximab up to a maximum of 2 years.


Eligibility criteria:
inclusion criteria: * male or female patient 18 years of age or older * pathological diagnosis of follicular lymphoma (any grade) or marginal zone lymphoma. patients with transformed follicular lymphoma are eligible, provided there has previously been pathologic documentation of follicular lymphoma. * documented relapse or progression following prior antineoplastic therapy * at least 1 measurable tumor mass that is greater than 1.5 cm in the long axis and greater than 1.0 cm in the short axis that has not been previously irradiated, or has grown since previous irradiation * no clinically significant evidence of active central nervous system lymphoma * karnofsky performance status (kps) ≥50 (equivalent to eastern cooperative group oncology group \[ecog\] status ≤2) exclusion criteria: * diagnosed or treated for a malignancy other than non-hodgkin's lymphoma (nhl) within 2 years of first dose, or who were previously diagnosed with a malignancy other than nhl and have any radiographic or biochemical marker evidence of malignancy. patients with prostate cancer who were treated with definitive radiotherapy who have a serum prostate-specific antigen \<1 ng/ml are not excluded. patients are not excluded if they have had basal cell or squamous cell carcinoma of the skin that was completely resected, or any in situ malignancy that was adequately treated. * received any of the following treatments or procedures outside of the specified timeframes: * prior treatment with velcade * prior treatment with a cumulative dose of doxorubicin of more than 100 mg/m2, if assigned to arm a (velcade-r-cap) * antineoplastic (including unconjugated therapeutic antibodies and toxin immunoconjugates), experimental, or radiation therapy within 3 weeks before day 1 of cycle 1 * nitrosoureas within 6 weeks before day 1 of cycle 1 * radioimmunoconjugates within 10 weeks before day 1 of cycle 1 * autologous stem cell transplant within 3 months before day 1 of cycle 1, or prior allogeneic stem cell transplant at any time * major surgery within 2 weeks before day 1 of cycle 1
twyshe - an mhealth peer-navigator intervention to increase prep and contraceptive use

Conditions: Hiv; Contraception Behavior

Summary: the goal of this clinical trial is to learn if the twyshe intervention can increase the use of hiv prevention in at-risk female university students aged 18-24 in zambia. the main question it aims to answer is: • can a mhealth peer navigator intervention effectively promote hiv pre-exposure prophylaxis prep use among high-risk female students in zambia? researchers will compare the mhealth peer navigator intervention to treatment as usual to see if there are effects on female student's use and continuation of prep for hiv prevention. participants in the intervention will be paired with a trained peer navigator who will offer education, social support, and help navigating the health systems to access prep and other sexual and reproductive health services. all participants in both arms will complete surveys at baseline, 6 months, and 12 months to evaluate health behaviors.

we are conducting a 1:1 individual-randomized, open-label single-site hybrid type 1 effectiveness-implementation trial to determine the effectiveness the twyshe intervention in lusaka, zambia. we will follow all participants for 12 months with regular data collection. all intervention activities will end at 6 months (primary endpoint window), but we will continue to follow and survey participants in both study arms at 12 months to determine long-term post-intervention effectiveness. prep and contraception uptake and persistence will be objectively verified using a study medical visit card filled out and signed by health providers. we will also collect and assess behavioral mechanisms hypothesized to be on the casual pathway, including participant knowledge regarding hiv and unintended pregnancy prevention, health beliefs (perceived risk of hiv or unintended pregnancy), perceived social support to access and adhere to hiv/unintended pregnancy prevention methods, stigma, behavioral intention to use prep and contraception, and self-efficacy to use prep and contraception. lastly, we will conduct exit interviews with peer-navigators and a sub-sample of participants to explore the implementation outcomes of the trial.

Eligibility criteria:
inclusion criteria: * female * aged 18 to 24 years * current university student * not diagnosed with hiv * self-report of 3 more hiv risk factors exclusion criteria: * male * less than 18 years of age * greater than 24 years of age * diagnosed with hiv * less than 3 self-reported hiv risk behaviors * not a university student

Keywords: hiv prevention modern contraception pre-exposure prophylaxis prep
telerehabilitation of patients after knee surgery

Conditions: Knee Osteoarthritis

Summary: this project is aimed to investigate the feasibility of employing communication and sensor technologies for the patient after a knee operation. in the study, it is hypothesized that the effectiveness of postoperative rehabilitation programs might be improved by establishing electronic communication between healthcare professionals and the patients. it is also believed that users satisfaction and patients quality of life will be improved. the telerehabilitation program promises a synchronized communication as well as an individualized training program (by health professionals) based on the patient's electronic reports.

aim the objectives of this project are to assess the feasibility of using a telerehabilitation program for patients after a knee operation and investigate the acceptance of the provided solution by the patients and healthcare professionals. hypothesis it is hypothesized that the acceptance and satisfaction of patients and healthcare professionals by using the telerehabilitation program will be high and correlated with patients' exercise adherence and health recovery. telerehabilitation group (target group) the subjects will be recruited before the operation and will be followed during an 8-week rehabilitation period. in addition to the telerehabilitation program, the subjects will receive the regular treatment offered by farsø hospital in connection with total knee replacement surgery and are to follow the same rehabilitation procedure as regular patients (see below). before the operation, the project physiotherapist will hand over the telerehabilitation system equipment and instruct the subject how to use the system. in addition, the physiotherapist will also ask the subject to follow the instruction process and try the available services a few times. the physiotherapist makes sure that the subject can operate the system easily and without any challenges.

Eligibility criteria:
inclusion criteria: * aged over 18 * successful primary total knee replacement surgery at farsø hospital * referred to the regular rehabilitation program (self-training at home) by the physiotherapists at farsø hospital * ability to walk (with or without walking aids) * able to use electronic technologies and devices (for example: smart phone, tablet) or at least one relative who can assist in this matter * living in the north denmark region exclusion criteria: * previous or current drug addiction defined as the use of cannabis, opioids or other drugs * previous or current neurologic, musculoskeletal or mental illnesses * any other aggravating medical complication (such as infection or dvt) * lack of ability to understand and accept trial procedures

Keywords: quality of life telerehabilitation knee rehabilitation knee osteoarthritis total knee replacement